Ulcerative colitis and Crohn’s disease

An overview of the diseases and their treatment
Ulcerative colitis and Crohn’s disease

An overview of the diseases and their treatment

J. Schölmerich, H. Herfarth and G. Rogler
Authors:
Prof. Dr. J. Schölmerich
Klinik und Poliklinik für Innere Medizin I
Klinikum der Universität Regensburg
D-93042 Regensburg
Germany

H. Herfarth, M.D.
Associate Professor of Medicine
University of North Carolina
Gastroenterology and Hepatology
4151 Bioinformatics Bldg.
130 Mason Farm Road
Chapel Hill, NC 27599-7080
USA

Prof. Dr. Dr. phil. G. Rogler
Universitätsspital Zürich
Klinik für Gastroenterologie
und Hepatologie
Rämistr. 100
CH-8091 Zürich
Switzerland

Associated authors of the 1st–16th editions
Prof. Dr. A. Fürst, Dr. P. Hoppe-Seyler,
Prof. Dr. M. Lausen
The informed patient

Contents

Foreword .................................................. 5

The names: Ulcerative colitis – Crohn’s disease 7

The digestive tract ................................. 9

Symptoms ............................................................. 12
The bowel
Other organs
Ulcerative colitis
Crohn’s disease

Methods of examination ...................... 17
Physical examination
Laboratory tests
Ultrasound
Endoscopy
Gastroscopy
Colonoscopy
Proctoscopy
Radiological examinations
Magnetic resonance imaging (MRI)
Computed tomography (CT)
Capsule endoscopy
Leukocyte scintigraphy
Endosonography
Follow-up studies

Causes ............................................................. 30
Bowel disease
Associated conditions
Complications
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>34</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>34</td>
</tr>
<tr>
<td>• Drugs</td>
<td></td>
</tr>
<tr>
<td>• Side effects</td>
<td></td>
</tr>
<tr>
<td>• Surgery</td>
<td></td>
</tr>
<tr>
<td>• Diet</td>
<td></td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td>39</td>
</tr>
<tr>
<td>• Drugs</td>
<td></td>
</tr>
<tr>
<td>• Nutritional therapy</td>
<td></td>
</tr>
<tr>
<td>• Surgery</td>
<td></td>
</tr>
<tr>
<td>• Deficiency syndromes</td>
<td></td>
</tr>
<tr>
<td>Psychotherapy</td>
<td>45</td>
</tr>
<tr>
<td>Special problems</td>
<td>46</td>
</tr>
<tr>
<td>Course of the disease</td>
<td></td>
</tr>
<tr>
<td>Fistulae</td>
<td></td>
</tr>
<tr>
<td>Osteoporosis</td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel diseases in childhood</td>
<td></td>
</tr>
<tr>
<td>The risk of cancer</td>
<td></td>
</tr>
<tr>
<td>Psychic stress</td>
<td></td>
</tr>
<tr>
<td>Self help groups</td>
<td></td>
</tr>
<tr>
<td>Disability and career</td>
<td></td>
</tr>
<tr>
<td>Recreation</td>
<td></td>
</tr>
<tr>
<td>Sex and partnership</td>
<td></td>
</tr>
<tr>
<td>Reproduction and genetic factors</td>
<td></td>
</tr>
<tr>
<td>Pregnancy</td>
<td></td>
</tr>
<tr>
<td>“Ileostomy”: the artificial bowel outlet</td>
<td></td>
</tr>
<tr>
<td><strong>What the patient should consider</strong></td>
<td>56</td>
</tr>
<tr>
<td><strong>Glossary</strong></td>
<td>58</td>
</tr>
<tr>
<td><strong>Self help groups</strong></td>
<td>61</td>
</tr>
</tbody>
</table>
Foreword

Every chronic disease represents a difficult challenge – for the patient, his family and for the physicians cooperating in his care. This is particularly true for diseases, the causes of which are only partially understood, and which are so rare that a typical family doctor may only see a few cases in his primary care practice. In Germany, the inflammatory bowel diseases (IBD) affect about one in every 250 to 500 persons. A person confronted with the diagnosis “inflammatory bowel disease” usually reacts first with great uncertainty. Many troubling questions come to mind: What does it really mean to have a chronic disease? What course will it probably take? How will it affect my life? And, what effects is it likely to have on my future? A survey of patients with IBD found that a majority felt that they did not possess sufficient information regarding their disease. While no brochure can replace frank discussions with your physician, every additional source of information is useful. It may be of particular help in assisting the patient in converting his uncertainties and anxiety into concrete questions that can then be discussed with his physician.

The present brochure is intended to be just such a source of information. We particularly hope to cover questions which, in our experience, are often posed by patients to their doctors. If, after reading this booklet, you find certain questions unanswered, please let us know. Your opinions are important to us and will help us to improve this brochure in future editions.

July 2006

J. Schölmerich, H. Herfarth, G. Rogler
Seite 6 = Vakat
The names: Ulcerative colitis – Crohn’s disease

You or a member of your family has been confronted with the diagnosis “inflammatory bowel disease” or IBD. In most cases, this means either ulcerative colitis or Crohn’s disease. At first, these names seem strange and you probably wonder what they can mean. Both refer to chronic inflammation of the mucosal lining of the intestine or bowel, though each has quite specific characteristics.

What do the names mean?

The use of different names is based on the fact that the disease is often named according to the portion of the bowel it affects and which becomes inflamed. The chart on page 11 shows the digestive tract and gives the names of the various segments.

Dr. Burrill B. Crohn
The small bowel is normally 3–5 m in length, while the large bowel or colon is about 1.5 m long. We distinguish between two main forms of IBD. The first is ulcerative colitis, an inflammation (“-itis”) affecting only the colon and associated with the formation of ulcers. In some cases, only the rectum is involved, and we speak of ulcerative proctitis (proctos = rectum).

The second main type of IBD is Crohn’s disease. Named for its discoverer, the American gastroenterologist Burrill B. Crohn, it can affect any portion of the digestive tract, from the mouth to the anus. Depending on the exact segments affected, we can speak of Crohn’s ileitis, ileocolitis, colitis or enteritis.
The informed patient

The digestive tract

What you should know about the normal digestive tract

The digestive tract or canal begins in the mouth. Here, the food is chewed and mixed with saliva, lubricating and partially digesting it. Once swallowed, the food passes into the esophagus, a muscular tube, whose walls move in wave-like patterns propelling the food downward into the stomach. In the stomach, the food is mixed with gastric juices, which consist of acid, mucus and various enzymes, which begin the breakdown of proteins. In the duodenum, the food is further mixed with secretions from the pancreas, which contain other digestive enzymes, and with bile. Bile is produced in the liver and contains bile acids, which also help in digestion. These functions are rarely compromised in ulcerative colitis, and, when they are, it is usually due to an associated disorder of the biliary tract. They are sometimes be affected in Crohn’s disease.

The upper segment of the small bowel, also known as the jejunum, is where fats, fat-soluble vitamins (A, D, E and K), protein breakdown products, sugars and some trace elements are absorbed. Vitamin B_{12} and bile acids, however, are absorbed in the ileum, the lower part of the small bowel. This latter function is often compromised in patients with Crohn’s disease, though disturbances of the upper small bowel are less frequent. The insufficient absorption and resulting loss of bile acids in the ileum, however, may adversely affect the digestion and absorption of fats and fat-soluble vitamins in the upper small bowel.
The colon’s main role is the absorption of water and minerals, which results in thickening and solidifying the stool. After advancing to the final segments of the colon (the sigmoid colon and rectum), the stool is formed and held back by the action of the bowel outlet or anus until a voluntary bowel movement occurs. These functions may be affected in both ulcerative colitis and Crohn’s disease. The result may be a tendency to unintended passage of gas or stool.
The informed patient

Mouth

Esophagus

Liver

Stomach

Gallbladder

Duodenum

Pancreas

Colon

Jejunum

Ileum

Rectum
Symptoms

What are the symptoms of ulcerative colitis or Crohn’s disease?

Both ulcerative colitis and Crohn’s disease are characterized by an inflammation of the mucosal lining of the bowel. Thus, some symptoms are common to both diseases. There are, however, fundamental differences due to the fact that the extent and location of the inflamed bowel segments differ between ulcerative colitis and Crohn’s disease.

Beside the general manifestations of disease, such as fatigue, tiredness, loss of appetite and sometimes fever, the specific symptoms are related directly to the bowel.

These include irregular bowel movements containing mucus and/or blood and severe diarrhea; abdominal pain, sometimes focused on a certain spot, but often affecting the entire abdomen, which can be crampy or persistent. Many patients experience nausea and may vomit. The inflammation may also result in loss of blood through the bowel. This loss, which may take the form of so-called “occult”, or hidden, blood and be detected only with special tests, may lead to anemia. Whenever there is loss of blood, iron is also lost: in this case, the bone marrow lacks the iron necessary to form new blood cells. This is known as iron-deficiency anemia.

Involvement of other organs in inflammatory bowel diseases (extraintestinal manifestations)
The informed patient

- Eyes
- Mouth
- Skin changes
- Liver and biliary tract
- Elbow joints
- Pancreas
- Iliosacral joints
- Knee joints
In both ulcerative colitis and Crohn’s disease, symptoms may occur not only in the bowel but also at other sites in the organism. Some patients experience inflammation (arthritis) in the larger and smaller joints of the arms and legs, as well as in the joints of the spine and pelvis. As in other types of arthritis, this joint inflammation results in swelling, pain and restrictions in motion. The skin in patients with IBD may also react in the form of painful purplish-red areas of thickening, most commonly occurring on the arms and legs (erythema nodosum).

Somewhat less frequent is inflammation affecting the eyes, particularly the iris and conjunctiva. In both, ulcerative colitis and Crohn’s disease, there may be rather uncharacteristic associated inflammation of the liver. In very rare cases, the bile ducts can undergo inflammation with extensive scar tissue formation resulting in jaundice and digestive disturbances. Other rare complications include inflammation of the pericardium (the sac surrounding the heart) and pancreas, as well as venous thromboses (blood clots).

Ulcerative colitis, which affects only the colon, is typically characterized in its acute phase by diarrhea mixed with mucus and/or blood. The severity of the diarrhea depends on the inflammatory activity and the extent of the inflammation. Diarrhea may be very severe in cases in which the entire colon is affected. If, however, only the final portions of the colon (the sigmoid or rectum) are affected, as in ulcerative proctitis, the stool may be more solid but traces of blood can be detected.

Crohn’s disease may affect both the small bowel and colon. In its initial phase, it may cause few or no symptoms at all and, particularly in cases in which the colon is only partially affected or completely spared, there may
be no diarrhea. In many cases, there may be **abdominal pain**, which sometimes can be confused with appendicitis. Crohn’s disease is associated with nutritional deficiencies in its early stages, resulting in significant weight loss. In some patients, the disease manifests with **inflammation in the region of the anus**, resulting in the formation of fistulae and abscesses. A fistula is a tube-like tract lined with inflammatory cells. It may connect two hollow organs or open into the outer skin or the anal mucosal membrane (see illustration on page 16).

Weeping, purulent fistulae in the region of the anus, particularly if they recur, should always suggest the need for more extensive examination of the bowel. Whenever a patient reports the occurrence of several of the above described symptoms, the physician will consider the possibility of IBD.
Perianal fistulae in Crohn’s disease (schematic illustration)
Methods of examination

What will the physician do to determine the type and extent of a patient’s disease?

He will inform you, the patient, that “diagnostic procedures” are now necessary, that you should undergo certain types of examinations.

As a first step, he will conduct a physical examination of your entire body, particularly the abdomen and also the rectum. He will gather information by palpating the outer surface of the body, by listening with the stethoscope and by tapping over hollow organs. This will help discover whether the skin, mucous membranes, eyes or joints show signs of disease. When examining the abdomen, it may be possible to determine the exact site of pain and the physician will be able to learn much about the condition of the liver and the activity of the bowel. In examining the anus, he will be able to recognize inflammation and, by gently examining the rectum with his finger, possibly find traces of blood.

The physician will then obtain blood and urine samples in order to perform certain laboratory tests, including erythrocyte sedimentation rate (time required for settling of suspended red blood cells), the number of white and red blood cells and platelets (the “blood count”), the protein content of the blood (protein electrophoresis and C-reactive protein [CRP]) and other special laboratory tests such as iron, electrolytes, vitamins (particularly vitamin B₁₂), folic acid and trace elements, such as zinc. Together, these tests help determine whether general signs of inflammation, absorption disorders (reduced
or inadequate uptake of nutrients from the bowel) or bleeding are present. The urine tests help evaluate the kidneys and urinary tract.

If the results of these tests confirm the suspicion of an inflammatory bowel disease, **further examinations** will be necessary to determine the type of the individual patient’s disease as well as its location and extent in the gastrointestinal tract.

**Ultrasound image:** longitudinal (lengthwise) slice through a section of the bowel that is ballooned with fluid held back by an area of narrowing (stenosis). In this slice, you see the stenosis as a thin, irregular black band (arrow). This black band is actually the remaining open interior of the bowel. The cross-sectional slice shows that the intestinal wall is thickened in the area of the stenosis (8–10 mm, compared with a normal wall thickness of 1.5–3 mm measured by ultrasound). (The figures have been made available by PD Dr. K. Schlottmann, Klinik und Poliklinik für Innere Medizin, Klinikum der Universität Regensburg, Germany).
The simplest and least invasive of all these methods is the **ultrasound examination of the abdomen**, also known as sonography. In most cases, ultrasound sensitively uncovers changes in the abdomen, such as widening of the bowel and thickening of its wall, changes in the liver, gallbladder and kidney stones, abscesses and any condition hindering the outflow of urine from the kidneys. Ultrasound is totally harmless and can be safely repeated as often as necessary. Thus, any suspicious findings can be re-examined and monitored.

In determining the **extent of the digestive tract** affected by any IBD, it is crucial to determine the exact site(s) of inflammation. A number of methods are available, including **endoscopy** and **radiography**.

Endoscopy uses an optical instrument to directly see the inner surface of hollow organs. Entering through the mouth, it is possible to examine the esophagus, stomach and duodenum. Entering through the anus, the physician can check the rectum, the entire length of the colon and usually the last few centimeters of the small bowel, also known as the terminal ileum. The endoscope is a flexible, tube-like instrument with a diameter of 9–12 mm. These high-precision instruments contain an optical system integrated into their tip connected to the outer end by a fiber-optic cable consisting of thousands of fine glass fibers. This fiber-optic cable transmits light into the organ being examined and conveys the image onto a television monitor. The endoscope has a separate channel through which a thin instrument can be introduced. This instrument, known as a biopsy forceps, can be used to obtain tissue samples for examination.

Endoscopy permits the examiner to look directly at the mucous membrane of the digestive tract. Normal tissue
can usually be easily distinguished from inflamed areas. In addition, tissue samples can be taken from affected areas and examined using microscopic methods, also known as histological examination. This direct examination under the microscope of samples of mucous membrane permits determination of whether inflammation is present, how severe it is, and what type of inflammation it is. Thus, it can establish the diagnosis of IBD and usually (≥ 90%) can differentiate between ulcerative colitis and Crohn’s disease.

Endoscopic examination of the stomach is also known as gastroscopy (see illustration on page 21). For gastroscopy, the optical instrument is introduced through the mouth and advanced through the esophagus into the stomach and duodenum. This examination must be done in a fasting state in order that the food content of the stomach will not interfere with inspection of the mucous membrane. The examination is painless; however, it is associated with unpleasant sensations of pressure in the neck during introduction of the instrument and in the upper abdomen. This discomfort can be significantly reduced by the administration of appropriate medication.

In colonoscopy (see illustrations on pages 23 and 24), which involves endoscopic examination of the bowel, the endoscope is introduced through the anus and advanced up the entire length of the colon to the entrance of the small bowel. Once the junction between the small bowel and colon (the ileocecal valve) is passed, the terminal portion of the small bowel can also be examined. Colonoscopy requires more intensive preparation. Patients are not permitted to consume any solid food for 24 hours prior to the examination. On the day before the examination, the patient may eat breakfast but for lunch, only clear broth is allowed. In the afternoon, the patient must also consume a suitable irrigating solution.
The informed patient

Gastroscopy
(3–5 liters) in order to cleanse the bowel. Various solutions are available with different tastes. After this, only mineral water or tea is allowed.

Colonoscopy may be painful, particularly when there are inflammation-related adhesions in the abdomen. Patients may be given injections that help relax them and relieve pain, making the examination tolerable.

**Proctoscopy** is the simplest and least invasive endoscopic method. It involves examination of the distal rectum and covers the last 5–10 cm above the anus. More commonly, however, patients undergo sigmoidoscopy, a procedure permitting inspection of the distal 30–40 cm of the colon. Prior to both procedures, the bowel is cleansed with an enema. Then, the examiner inserts either a short, stiff tube (rectoscope) or a short flexible endoscope (sigmoidoscope). Both procedures offer the capability of obtaining tissue samples (biopsies). Both methods are sufficient for evaluation and follow up of inflammation in the area of the rectum.

**Radiological examinations** represent another option for examining the digestive tract. One method makes use of a solution (contrast medium) that is not penetrated by x-rays to show the contours of the esophagus, stomach, small bowel or colon. In cases of IBD, examination of the small bowel is particularly important. In such cases, the small bowel can be examined using a special method developed by and named for the radiologist Sellink. In this method, a tube is passed through the stomach into the duodenum (see illustration on page 25). This permits direct application of a diluted contrast medium in the small bowel. The segments of the small bowel between the duodenum and colon, which are not accessible to endoscopy, can be examined using this method.
Colonoscopy
Colon – normal findings

Crohn’s disease – chronic inflammation with pseudopolyps

Ulcerative colitis – severe inflammation
New possibilities have become available for imaging the small bowel using **magnetic resonance imaging (MRI)**. MRI generates “slices” of selected regions of the human body (see illustration on page 26). Unlike the Sellink procedure, MRI does not involve any radiation. Various techniques have been developed to optimize imaging of the small bowel with MRI. Depending on the technique used, it may be necessary in some cases to insert a tube into the duodenum. In many cases, however, it is sufficient to simply drink fluids (for example, water or pineapple juice), which act as contrast media in the small bowel.

Another method for imaging the abdomen is **computed tomography (CT)**. As in MRI, CT generates slices of selected regions of the body. Unlike MRI, however, CT requires the use of radiation. CT is particularly useful in the search for abscesses (encapsulated collections of pus), which are frequently encountered in IBD.

Two new endoscopic techniques include **capsule endoscopy** and **double balloon endoscopy**. Capsule endoscopy makes it possible for the first time to examine the small bowel in its entirety. This was formerly possible only indirectly using radiological methods. Un-
Fortunately, capsule endoscopy, while permitting us to inspect the small bowel, lacks the capacity for tissue biopsy. The method is also not suitable for examination of the stomach or colon. For patients with Crohn’s disease, capsule endoscopy is associated with a certain risk because, although the endoscopy capsule is relatively small, it may still become trapped in an area of stenotic bowel. In the worst case, this can result in acute intestinal obstruction, requiring immediate surgery. At present, capsule endoscopy has not become an established option in the diagnosis of inflammatory bowel diseases and should only be used when answers to very special questions are being sought. Future
studies will determine the value of capsule endoscopy for therapeutic decision-making in areas in which this method can provide additional information.

The second new endoscopic technique is double balloon endoscopy, which uses a specially designed endoscope permitting examination of significantly longer stretches of the small bowel than has been possible using conventional endoscopes. Unlike capsule endoscopy, double balloon endoscopy has the capacity to obtain tissue specimens from the small bowel, as well as to stop bleeding and remove polyps. It is possible that, in the future, this technique will make it possible to dilate narrowed areas of the bowel (stenoses) that to date require surgery. As with capsule endoscopy, the benefit of this method for patients with confirmed inflammatory bowel diseases must be evaluated in further studies.

You may now be asking yourself whether all of these examinations must be performed. You can relax. The more extensive array of methods is normally required only to confirm the initial diagnosis of a disease and to determine its extent and severity.

The choice of method depends on individual factors, particularly the patient’s current physical condition. Endoscopy and radiological methods can be used to complement each other. Usually, endoscopy is used to examine the more easily accessible segments of the digestive tract, since radiation exposure is avoided and it is normally possible to obtain tissue samples (biopsy) from suspicious areas for microscopic evaluation. In order to properly evaluate the small bowel, as well as in cases in which the presence of fistulæ or severe narrowing (stenosis) in the colon are suspected, it will not be possible to avoid radiologic examinations. The exact
analysis of fistulae and/or abscesses can often be done using a special ultrasound examination of the rectum (endosonography) or with MRI.

In endosonography, an ultrasound transducer head is introduced through the rectum as in proctoscopy or sigmoidoscopy. This permits ultrasound examination of underlying tissue and determination of possible fistula formation.

How does the physician monitor the course of inflammatory bowel diseases?

It is important for you, the patient, to understand that, while both ulcerative colitis and Crohn’s disease are chronic diseases of the bowel that can become and remain inactive, careful medical attention is crucial for monitoring and control of your disease. This means regular visits to the physician: at least twice a year is recommended, even when you are free of symptoms. If, however, drugs are required to control your disease, follow-up examinations should be done at least every three months. Beside a physical examination including palpation of the abdomen and examination of the bowel, patients undergo blood tests that help identify signs of inflammation or of nutritional deficiencies. At least once a year, the physician will order an ultrasound examination of the abdomen. If there is no evidence of inflammation, the more complex examination methods can usually be avoided.

During an acute disease episode or flare-up, patients do not necessarily have to re-undergo the entire battery of tests. In those cases in which symptoms are significantly different than in earlier disease phases, however, it may be helpful to re-assess the extent of the disease,
since changes may occur, possibly necessitating a modification in treatment strategy. In **ulcerative colitis**, this is particularly important in cases in which the initial extent of the disease did not involve the entire colon. In **Crohn's disease**, significant changes in symptoms usually necessitates re-examining both the small bowel and colon in order to exclude the presence of fistulae, stenoses or other complications. If, however, there are no changes and the disease remains inactive, these invasive methods are not necessary. Patients who have suffered from ulcerative colitis for a long period of time (more than 10 years), however, should undergo regular colonoscopy (once a year is recommended) in order to exclude the development of malignant tumors in the bowel. This is particularly important in extensive colitis.
What causes inflammatory bowel diseases?

Despite numerous studies, the actual cause of the inflammatory bowel diseases remains elusive. It is likely, however, that these chronically recurring episodes of inflammation in the human bowel are related to a complex interaction between various environmental factors and a hereditary predisposition for these diseases. In recent years, research has identified various sites (genes) within the human genome that may be associated with these diseases. To date, changes in several genes have been discovered that play a greater or lesser role in the development of Crohn's disease. The most important of these changes of the genetic material in patients with Crohn's disease was identified by scientists in 2001. They showed that changes (mutations) in the so-called NOD2/CARD15 gene significantly increase the risk of developing Crohn's disease. Such changes appear to be at least partially responsible in about 20% of all Crohn's patients for the occurrence of this disease. On the other hand, it is clear that this hereditary predisposition alone cannot lead to the outbreak of disease: this requires the presence of further, as yet unidentified factors. Changes in the NOD2/CARD15 gene are found in about 4% of individuals, who do not develop this disease. This means that genetic predisposition requires the action of other, still unknown factors in order for an affected individual to actually develop the disease. These factors may include viruses or bacteria, changes in nutritional behavior or the consumption of certain preservatives or other food additives, as well as disturbances of the body's own immune defense system or the intestinal barrier. To date, no definitive evidence has been found to prove a connection between these factors
and the development of inflammatory bowel disease. It is, however, very probable that environmental factors play a role. Crohn’s disease, for example, is much more common in Western industrial nations than in other regions of the world. On the other hand, it is very unlikely that IBD is due to an underlying infectious disease – hence, infecting other persons with the disease is not possible.

The role of psychological factors remains controversial. While psychic stress may, under certain circumstances, provoke an acute flare-up of an existing disease, it is not the underlying cause of inflammatory bowel disease.

We also do not know the exact reason why many patients with IBD also suffer from inflammatory changes in other organs, such as the joints, skin or eyes. One explanation is an overreaction on the part of the body’s immune defenses to either invading microbes or even the body’s own tissues. This, however, has not yet been proven.

On the other hand, the causes of many other complications of these bowel diseases are known. For example, the reduced absorption of vitamins and some trace elements (minerals) in patients with IBD is responsible
Complications outside of the bowel due to disturbed bowel function in IBD

- Alopecia (hair loss)
- Vision defects
- Hearing loss
- Taste sensation abnormalities
- Skin
- Gallstones
- Kidney stones
for symptoms such as night blindness, deafness, changes in taste sensation, vulnerability to infection, hair loss, infertility (in men), growth retardation (in children) and certain skin changes frequently seen in these patients. Anemia may be caused by iron deficiency, by loss of blood from the bowel or by vitamin B\textsubscript{12} malabsorption. A reduced uptake of bile acids in the small bowel and an increased absorption of bilirubin in the colon is responsible for the increased risk of gallbladder stones, while kidney stones may result from the increased loss of water.

In both main types of IBD, serious complications such as acute ballooning of the bowel (“toxic megacolon”) or perforation, the formation of a hole in the wall of the bowel, may occur in a few patients. Peritonitis, the inflammation of the membranous lining of the abdomen, and intestinal obstruction or paralysis (ileus) may result. These are life-threatening conditions requiring immediate hospital admission and often emergency surgery. Extensive intestinal hemorrhage occurs most often in patients with ulcerative colitis. Stenoses caused by inflammation or scar tissue formation and fistulae between the bowel loops and other organs are direct consequences of Crohn's disease.
**Treatment**

As the name “chronic inflammatory bowel diseases” implies, both ulcerative colitis and Crohn’s disease are chronic disorders. This means that the patient will continue to have them for the rest of his or her life. The progression of the disease, however, can differ significantly from patient to patient. While some individuals experience very mild disease with infrequent flare-ups, others will suffer from much more severe disease with frequent hospitalizations. It is, unfortunately, impossible to predict at the outset the comparative severity of an individual patient’s future clinical course. Large studies, however, have shown that more than half of all patients with ulcerative colitis or Crohn’s disease tend to exhibit a mild clinical course and do not require even one course of treatment with cortisone preparations.

**What treatment methods are available?**

Treatment options fall into four main groups and include drugs, surgery, diet and supportive measures. One very important supportive measure is for the patient affected with Crohn’s disease to quit smoking. Compared to smokers, patients who quit smoking have a 60% lower chance of experiencing disease recurrence within a two-year period.

**Treatment of ulcerative colitis**

The primary goal of treatment is to improve patients’ symptoms (diarrhea, pain, blood loss) and, once this is successful, to prevent recurrence.
The usual first step is the use of drugs. The choice of therapy depends on the severity of patients’ symptoms. In cases with mild to moderately severe inflammation, 5-aminosalicylic acid is often prescribed. In patients in whom the joints are also affected, sulfasalazine can be tried. This drug, discovered in 1942 by the Swedish physician Nanna Svartz, was the standard treatment for ulcerative colitis prior to the introduction of 5-aminosalicylic acid.

5-aminosalicylic acid, also known as mesalazine, is a specially manufactured agent designed to be released in the lower third of the small bowel and in the upper two-thirds of the colon. In those cases in which ulcerative colitis affects only the rectum or left side of the colon (up to 80% of patients), the disease may respond to suppositories, enemas or rectal foams that contain either 5-aminosalicylic acid or cortisone preparations. Enemas containing the locally acting cortisone derivative budesonide are also effective and are associated with a significantly lower occurrence of side effects in

Dr. Nanna Svartz
the body. In severe cases, the administration of cortisone preparations either as pills or injections is usually effective.

If cortisone in the form of tablets or enemas does not lead to an improvement in a patient’s symptoms, the physician may recommend medications that reduce the body’s immune reactions. These drugs are frequently effective because, as we noted above, chronic inflammatory bowel diseases represent a disorder in which the body’s immune system has been misdirected against its own tissues.

If this type of treatment is selected, the first drugs tried are usually azathioprine or 6-mercaptopurine. Their maximum effect, however, becomes apparent only after 10–12 weeks of therapy. Unfortunately, not all patients respond to these drugs and about 10 in 100 patients experience significant side effects, including acute hepatitis, acute pancreatitis or a disorder of blood cell formation. Hence, patients must undergo regular (weekly, then biweekly) laboratory tests of liver and pancreatic function and complete blood counts. If these tests remain normal for three months, the test frequency can be reduced to every 2–3 months.

If azathioprine or 6-mercaptopurine successfully prevent disease recurrence, they should be taken for at least four years. Within this time period, patients must practice a secure form of contraception.

If an ulcerative colitis flare is very severe and cortisone therapy does not result in any improvement, patients should be hospitalized. In such cases, cyclosporine can be administered intravenously for 24 hours. Cyclosporine was originally developed for use in patients with kidney transplants to suppress the body’s rejection of the transplanted organ.
The informed patient

If cyclosporine proves ineffective, the last option is the surgical removal of the colon (colectomy).

Patients in whom therapy results in resolution of complaints (remission) are usually started on 5-aminosalicylic acid in order to maintain their status of disease remission.

A very important point in the therapy of ulcerative colitis is that the choice between the various preparations and the method of administration depends on the extent and activity of the disease. This fact explains the importance of a complete examination before treatment and in cases in which the pattern of symptoms has changed.

In determining the best treatment strategy, the physician will take into consideration the severity of the flare-up and the extent of inflammation. In any case, the drugs must be taken long-term, that is, even after symptoms have resolved. Long-term administration of 5-aminosalicylic acid preparations has been shown to effectively prevent a new flare-up of the disease. As with all medications, undesired side effects may occur. These include headache, stomach complaints, nausea, anemia and hair loss. These side effects, however, are rare and resolve once administration of the drug has been stopped. The detailed description of these side effects on the package insert should not cause you to stop taking the drug out of fear. Instead, you should always consult your physician who will use appropriate methods to determine whether, in your case, the administration of the drug should be stopped or the dosage changed. Complications are more frequently due to patients’ discontinuing their medication without consulting their physician than to side effects of the drug themselves. This is also true for patients who are, for the moment, free of complaints.
Recent studies have shown that disease recurrence in ulcerative colitis can be effectively blocked by the administration of so-called **probiotics**. Probiotics influence the bowel’s bacterial flora and include such agents as *Escherichia coli* Nissle and various lactobacilli. They appear to be as effective as 5-aminosalicylic acid. This method is particularly attractive in patients who do not tolerate 5-aminosalicylic acid. The efficacy of this method, however, has not been substantiated in the treatment of Crohn’s disease or of the acute disease phase of ulcerative colitis.

Beside the testing of new drugs, several new and interesting therapy concepts exist that are currently being investigated in clinical studies. Examples are the removal of certain cell types from the blood using blood filters similar to those used in dialysis in patients with chronic kidney failure (cell apheresis) and the inhibition of various, recently discovered mediators of inflammation. As with all new therapeutic methods, studies must comprehensively investigate both their effects (here, the success of therapy) and possible side effects.

Because of the success associated with drug treatment, surgery is rarely necessary. Life-threatening complications (see page 33), severe complaints persisting despite adequate drug treatment and serious drug-induced side effects are indications for surgery.

The **surgical removal of the entire colon** cures ulcerative colitis. In many cases, it may be possible to remove the colon without the need for a permanent “ileostomy” or artificial bowel outlet in the abdominal wall. This usually involves surgical creation of a “pouch” out of loops of small bowel that acts as a reservoir and substitute for the rectum (see illustration on page 40). In most cases,
this results in almost normal stool consistency and a bowel movement frequency of about five to eight times per day.

Patients with ulcerative colitis do not require a special diet. It is advisable, however, to avoid foods such as cabbage, onions or high-fat items that may cause complaints even in healthy persons. In our experience, it is usually best for each patient to test his or her own individual tolerance to different foods. Nutritional deficiencies occur very rarely in patients with ulcerative colitis. These may manifest themselves as edema (swelling due to accumulation of water in various tissues caused by protein deficiency) or anemia (due to blood loss or iron deficiency) occurring most often in instances of prolonged disease flare-ups. They respond to substitution of the appropriate substances.

Disease manifestations outside of the bowel (joints, skin, eyes) can also be successfully treated with medication, usually with preparations containing cortisone. Surgical or dietary measures are usually less effective. Changes occurring in the biliary tract are often treated with ursodeoxycholic acid (UDCA), a bile acid. UDCA does not “cure” these conditions but may significantly slow their progression. Every case of abnormal “liver enzymes” requires careful study and appropriate treatment.

The treatment of Crohn’s disease

The treatment of Crohn’s disease is based on the same principles as that of ulcerative colitis. Because of the more divergent pattern of disease, symptoms and complications, however, it is more challenging to establish the optimum treatment for each individual patient.
Acute flare-ups are usually treated with **cortisone preparations**. There are preparations containing **budesonide** introduced for the treatment of Crohn’s disease (especially the last part of the small bowel, terminal ileum). Their efficacy is similar to that of cortisone and its derivatives. Because their effects are limited to the bowel and the overwhelming proportion of the drug is de-activated in the liver prior to reaching the general circulation, these agents are associated with a significantly lower rate of side effects. Crohn’s disease can also be tackled with dietary measures. Patients can convert their dietary intake to the so-called “astronaut diet”, consisting of substances wholly digested and absorbed in the upper gastrointestinal tract. Nourishment can also be administered through **infusions** of nutrient solutions directly into the bloodstream. Dietary measures are usually associated with lower chances of success. In cases in which the inflammation is restricted to the small bowel, cortisone preparations are normally used first. If the colon is affected, **5-aminosalicylic acid** may also be tried. If patients do not respond to either of these drugs, intestinal **antibiotics** (metronidazole) or drugs that suppress the **immune system** (for example, azathioprine) may be added. All of these drugs may be associated with side effects, such as itching sensations in the arms and legs, hair loss, anemia, increased risk of colds and the like. Should these or other side effects occur, it is important to consult your physician, who will advise you on the proper course of action. In any case, you should not stop taking your medication or change its dose without asking your doctor. In most cases,

*In the pouch operation, the whole colon is removed with the exception of a small section of the lower rectum. A pouch is then created out of a part of the small bowel (terminal ileum) and sutured to the remaining portion of the rectum.*
The technique of stricturoplasty. A longitudinal (length-wise) incision is made in the area of stenosis and then the bowel is closed in a cross-wise fashion.
The informed patient

these drugs successfully treat **acute flare-ups** of Crohn’s disease. The same is true for manifestations of the disease occurring outside of the digestive tract. The use of 5-aminosalicylic acid preparations has been shown to reduce the recurrence of the disease after surgery, though this effect is unfortunately less pronounced following successful treatment with cortisone. Newer treatment methods, such as **inhibition of tumor necrosis factor** (TNF), a messenger substance in the body (e.g. infliximab), should only be tried if the above described drugs have proven unsuccessful.

If these methods prove unsuccessful, or if complications such as intestinal obstruction or repeated stenoses occur, **surgery** may provide long-term relief. When surgery is recommended, emphasis is placed on techniques that preserve as much bowel as possible. Short areas of narrowing (stenoses or strictures) can be relieved using a technique called stricturoplasty (see figure on page 42). This involves placing a longitudinal (lengthwise) incision into the area of stenosis and then closing the bowel in a cross-wise fashion. This relieves the narrowing and normal passage of stool is again possible. The main advantage of this method is that no bowel must be sacrificed. Stricturoplasty can be performed on several segments of stenosed bowel during a single operation. Surgery must also be considered for the treatment of fistulae. Abscesses are usually treated today by means of a **drainage** placed through the skin under ultrasound or computed tomographic guidance. Surgery, however, is usually required after the acute symptoms have subsided to treat the underlying cause, which may be a fistula or stenosis of the bowel. Following successful surgery, it is advisable to undergo regular follow-up conducted by experienced internists and surgeons working together. This permits early recognition and treatment of any complications that may arise.
Normal colon

Severe inflammatory changes in the colon with pseudopolyps
Unlike ulcerative colitis, Crohn’s disease is associated with a number of different nutritional deficiencies, including vitamins, trace elements, minerals and protein. This requires appropriate substitution (vitamins, calcium, iron, potassium, zinc). Your doctor will use regular blood tests to identify the exact nutrients that require substitution. One very common deficiency is that of vitamin $\text{B}_{12}$, where absorption from the bowel is often reduced in Crohn’s disease. In order to prevent a deficiency of vitamin $\text{B}_{12}$ and the resulting anemia, the life-long administration of the vitamin by injection every three months may often be necessary.

As in ulcerative colitis, patients with Crohn’s disease must determine for themselves which foods they tolerate and which foods cause them problems. A balanced diet providing the necessary nutrients, vitamins and minerals should be the goal.

To date, no special diet or nutritional form has been proven to either accelerate treatment or prevent recurrence.

**Psychotherapy**

Different researchers have expressed different opinions on the need for and expected success of psychotherapeutic treatment. On the one hand, it is certain that inflammatory bowel diseases cannot be cured by psychotherapy. Whether such therapy can help prevent a flare-up in patients with psychic stress is not known. It is probable, however, that a behavioral therapy that helps patients better cope with the problems of their disease and of daily life could be useful. In any case, such a treatment should only be conducted in cooperation with your physician.
Special problems

What kinds of special problems may occur?

Now that we have discussed the issues of the development, diagnosis, treatment and follow-up in cases of inflammatory bowel disease, we will turn to a few special problems that must be confronted by patients living with these diseases.

Course of the disease

Probably the most important question you will wish to discuss with your physician deals with the future course of your disease: how will it progress and what problems will confront you in the future? When discussing your prognosis (that is, the probable future course of your disease), your physician will explain that, in individual cases of inflammatory bowel disease, reliable predictions are often possible only after fairly extensive periods of observation. We know today that patients’ life expectancies are not reduced in either ulcerative colitis or Crohn’s disease, provided they are correctly diagnosed and appropriately treated. Ulcerative colitis and Crohn’s disease are chronic diseases that will affect your life for years to come. Both diseases tend toward an episodic pattern of activity, alternating between symptom-free and active disease states. Early diagnosis and appropriate treatment can usually suppress the inflammatory activity and lead to re-establishment of an inactive disease phase. Complications are more likely in patients in whom the inflammation has become chronic and has led to progressing changes in the bowel. The most effective way of reducing the risk of complications is regular follow-up by your physician who can recognize inflammatory
flare-ups early and institute appropriate treatment. Flare-ups and associated complications can severely reduce your quality of life and overall happiness. Thus, minor side effects of special drug therapy can be tolerated with this larger goal in mind.

**Fistulae**

About one-third of all patients with Crohn’s disease experience the development of fistulae. Fistulae represent a kind of short circuit connection between individual bowel loops or may form between the bowel and other organs, such as the urinary bladder, vagina or the skin. The most common site affected by fistula formation is the tissue surrounding the anus. In this area, the fistula forms a connection between the rectum and the skin surrounding the anus (see diagram on page 16). The development of fistulae is associated with certain com-

*Ultrasound image showing a fistula tract linking the bowel with the skin*
plications, including the formation of abscesses (encapsulated collections of pus). When the formation of fistulae is suspected, the physician will perform certain diagnostic procedures. Depending on location, these include radiologic examinations such as CT or MRI, proctoscopy and/or endosonography. The therapy of fistulae depends on their location and associated complications. Because of the associated inflammatory reaction, treatment may begin with the administration of antibiotics. In certain cases, however, it may be necessary to surgically remove the fistula or the bowel segment from which the fistula originates. This is often recommended in cases of fistulae that form between two bowel loops or when complicated by extensive abscess formation. In the longer term, most patients will ultimately require either surgical or immunosuppressive (e.g. azathioprine) therapy to definitively close the fistulae. A new treatment method involves the suppression of the messenger substance, tumor necrosis factor (TNF). This, however, usually results in only temporary closure of the fistula and the method should be reserved for patients who do not respond adequately to the above-described medical or surgical treatments. To date, however, no totally satisfactory method for treating fistulae has been devised. However, in most patients treatment is successful.

**Osteoporosis**

Over half of all patients with inflammatory bowel diseases suffer from reduced bone mineral content. While such bone loss can be mild or severe, both forms respond to drug treatment. Patients’ bone density should be measured especially in cases of long-term administration of cortisone preparations. Bone density is measured using radiologic methods that expose the patient to relatively low doses of radiation. Therapy in mild forms of bone
loss consists of the administration of vitamin D and calcium. More severe bone loss may require the use of other drugs (bisphosphonates). These drugs directly inhibit bone destruction but are associated with a higher rate of side effects than vitamin D and calcium.

Inflammatory bowel diseases during childhood

It would appear that the frequency of Crohn’s disease in children is increasing. Thus, children and adolescents should be just as carefully examined and treated as adults. An additional problem in these young patients is the fact that both the chronic bowel inflammation and, in some cases, the necessary drugs may result in disturbances of physical development. In such cases, as well as in patients who do not respond to drug treatment, surgery must be considered. This will at least temporarily remove the site of inflammation.

Children by nature are more greatly affected than are adults by psychic stress. They also suffer more profoundly under the effects of chronic diseases and therefore should be seen by a child psychiatrist as early as possible after first diagnosis. More so than with adults, it is advisable that the treatment of inflammatory bowel diseases in children should be conducted in cooperation between the child’s family doctor and a clinical center.

The risk of cancer

The well-informed patient understands that the danger of cancer is associated with any chronic inflammation that persists for a long period of time. What does this mean, however, for patients with ulcerative colitis or Crohn’s disease?
Studies have shown that there is an increased risk of cancer in patients with ulcerative colitis in whom the entire colon is affected and in whom the disease starts early and has persisted for more than 10 years. For this reason, all patients who have suffered from ulcerative colitis for longer than 10 years should undergo endoscopic examination of the colon at least every two years. This is the only way to detect the early signs of malignant degeneration, such as mucous membrane dysplasia. If discovered in time, this abnormal tissue can be removed surgically, thus preventing the development of cancer. The risk of cancer is significantly lower in Crohn’s disease. However, when only the colon is affected, colonoscopy should be performed every two years in patients whose disease has persisted more than 10 years.

Psychic stress

The realization that you have been diagnosed with a chronic disease and will be confronted with it and its associated problems for many years to come naturally affects your personal sense of intactness and psychic constitution in a very profound way. What can you do in order to better cope with these problems?

Rule number one: You must confront your disease, then come to terms with it and accept it. You have the advantage of recognizing your disease, an advantage not shared by many other people. Coping with such a disease has its purpose and can be a source of enhanced self-confirmation and worth.

Rule number two: You must not let your illness control you. Those who lose courage suffer the most from their disease. You must actively confront your disease and
live a normal life – despite and even because of your disease. All means of actively confronting your disease are open to you. First and foremost, of course, are rational medical treatment and drugs. However, other alternatives – again, after consultation with your doctor to prevent undesired consequences – are preferable to losing heart and doing nothing. Disease attacks the individual as a whole. All therapeutic measures must therefore also treat the person as a whole.

Self help groups

You are not alone in your disease. Coping with a chronic or other long-lasting illness can be made much easier by talking about it and its problems with others suffering from the same disease. Self help groups and associations have been formed in many towns and countries. The appendix offers more information on such groups in your country.

Disability and career

You are unable to work during the active phase of your disease. This is equally true for inflammatory bowel diseases as for any other disease and applies to every profession or line of work. Because of the typical chronic, episodic course of the disease, you must be prepared, whatever your work, for short, disease-related periods of disability. However, job re-training or giving up a career are only necessary in a few individual cases. Under certain circumstances, such as after major abdominal surgery, the presence of fistulae or in patients whose disease has not responded adequately to medical treatment, heavy physical work is not advisable.
Such patients, however, can normally perform other jobs involving only light physical activity or that can be performed in seated position.

Adolescents, in whom there has been an increased occurrence of inflammatory bowel diseases in recent years, should particularly be encouraged to complete their vocational or professional training.

Recreation

Similar considerations apply to recreation as apply to work and career. All options remain open to you despite your disease. Only in phases of severe inflammation should certain restrictions be placed on your physical activity. With the exception of high-performance sports, physical activity in any form is fully recommended. This is true even in patients undergoing long-term drug treatment. In fact, particularly in patients receiving cortisone preparations, regular exercise of the muscles, joints and bones is highly recommended and may help reduce or prevent some of the side effects of these drugs.

It is also normally possible to take vacations in foreign countries. The required vaccinations, however, should be given only after consultation with the physician treating your IBD, though, as a rule, there is no reason not to get them. One special factor is the long-term treatment of Crohn’s disease with the antibiotic, metronidazole. Patients receiving this drug should protect themselves from direct sunlight and avoid alcohol.
Sex and partnership

Here, too, no specific restrictions are required. Sexual activity will naturally be reduced during an acute disease flare-up. In females, the body’s natural mechanism for conserving its energies and resources may result in interruption of menstruation.

The formation of fistulae in patients with Crohn’s disease may, in certain cases, affect the internal and external genital organs, resulting in a mechanical restriction of sexual activity. Such fistulae require intensive medical attention and drug therapy. Thus, prompt consultation of a physician is advisable.

Reproduction and genetic factors

In our discussion of the causes of inflammatory bowel diseases, we noted that genetic predisposition probably plays a role in both ulcerative colitis and Crohn’s disease. Should this be considered a reason not to have children?

The probability of inheriting a predisposition to inflammatory bowel disease is low. Thus, the risk that children of persons with IBD will develop either ulcerative colitis or Crohn’s disease is therefore not considered to be very high. This small risk should not deter persons affected by IBD from having children.
Pregnancy

This section is closely related to the last. Is it advisable for women with IBD to become pregnant and should these women attempt to carry pregnancies to term and deliver normally?

In answering these questions, it is important to state at the outset that pregnancy has not been shown to adversely affect the clinical course of either ulcerative colitis or Crohn’s disease in any way. Thus, the decision to conceive can be supported in patients who desire children. It is, of course, important to plan the pregnancy, so that it does not occur during a period of more pronounced disease activity. During pregnancy, patients should be carefully monitored in cooperation between an internist and gynecologist. Should an acute disease flare-up occur during pregnancy, treatment with cortisone and 5-aminosalicylic acid preparations is possible. Careful administration of these drugs will control inflammatory activity without producing side effects in the embryo. Patients undergoing long-term treatment with azathioprine, however, should use contraception. The two most effective methods of birth control, the pill and the intrauterine device (IUD), are both somewhat controversial in patients with IBD. The best form of contraception must be individually decided, if possible, by an internist and gynecologist working together.

“Ileostomy”: the artificial bowel outlet

Newly developed surgical techniques make it possible in many cases of ulcerative colitis to remove the entire colon without permanent creation of an artificial bowel outlet, or “ileostomy” (see illustration on page 40). In fact, a permanent ileostomy is required only in very rare
The informed patient

cases. The creation of a temporary ileostomy in patients with ulcerative colitis and Crohn’s disease may, however, actually have a beneficial effect on the disease. The ileostomy is usually closed after four to six months. Modern ileostomy appliances make it possible to live a practically normal life, including sports and sexual activity, despite the artificial bowel outlet. Early retirement due to a permanent ileostomy is necessary only in the rarest of cases.

If, however, your disease and its treatment do require the placement of an artificial bowel outlet, you should contact and listen to the experiences of others who have been in your condition. Ileostomy patients have formed self help groups in many cities and countries. Once again, we refer you to the appendix for a list of groups and contact information.
What should you keep in mind, as a patient with inflammatory bowel disease?

1. Maintain regular medical follow-up even in phases when your illness is in remission. Patients with complications should seek rapid referral to a gastroenterological center in which internists and surgeons will cooperate in your care.

2. Inform yourself about possible dietary measures and consult a reputable dietician.

3. Never forget: the more you control your disease the less your disease will control you.

4. If your physician prescribes a long-term drug therapy regimen, you must comply with it as closely as possible. Medications should be discontinued or their dose changed only after consulting with the responsible physician. Ask your doctor about possible side effects and about how to recognize them.

5. Learn to recognize the signs of increased disease activity. In ulcerative colitis, these include changes in the stool up to and including bloody diarrhea, abdominal pain and general signs such as tiredness and fatigue. In Crohn’s disease these include abdominal pain, weight loss, changes in stool (diarrhea or constipation) and general deterioration in physical performance. In both diseases, there may be symptoms outside the bowel, including pain in the joints, inflammation of the eyes, changes in the skin and mucous membranes, back pain and renal colics. You should inform your doctor immediately if these signs are recognized. These symptoms may not
always be due to IBD, however. Often, they may be due to dietary mistakes (for example, diarrhea following consumption of raw fruit) or bowel infections, which may occur as well in patients with IBD.

6 Inform yourself about your disease and about your individual case. It may also be helpful to keep a diary or journal. In any long-term disease, it is probable that a number of physicians, independent of each other, will be involved in your care. Collect information on the examinations you have undergone as well as surgical reports. Important are the names and addresses of the physicians and hospitals who examined you or performed operations or other procedures, as well as the date and measures undertaken. You yourself should know how extensive your inflammation is and what treatment methods have already been tried. Also note any side effects or intolerance to medications.
Abscess Encapsulated collection of pus occurring in areas of inflammation due to bacteria

Anemia An abnormality of the blood caused by a deficiency of hemoglobin or in the number of red blood cells (erythrocytes)

Colon The large bowel

Duodenum First segment of the small bowel

Dysplasia Abnormal development of tissue. Dysplasia may occur in different degrees of severity and may be considered a precursor of cancer of the bowel

Erythema nodosum Violet-red thickening of the skin, usually on the arms or legs

Fistula Abnormal, “short circuit” connection between two bowel segments, between the bowel and the bladder or vagina, or between the bowel and the skin occurring as a result of inflammation

IBD Inflammatory bowel disease

Ileocecal valve Valve-like structure forming the junction between the lower segment of the small bowel (ileum) and the colon

Ileum Final segment of the small bowel

Ileus Obstruction of the bowel caused by narrowing (stenosis) or paralysis
<table>
<thead>
<tr>
<th>Medical Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immuno-suppression</td>
<td>Therapy aimed at inhibiting the body’s immune system</td>
</tr>
<tr>
<td>-itis</td>
<td>Suffix denoting inflammation. For example, “colitis” means inflammation of the colon</td>
</tr>
<tr>
<td>Jejunum</td>
<td>Middle segment of the small bowel</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>Loss of bone tissue or changes in the overall form of the bone resulting in reduced mechanical strength and a tendency to fracture</td>
</tr>
<tr>
<td>Perforation</td>
<td>Formation of a hole in the wall of a hollow organ, such as the bowel</td>
</tr>
<tr>
<td>Peritonitis</td>
<td>Inflammation of the membrane lining the inner surface of the abdomen</td>
</tr>
<tr>
<td>Pouch</td>
<td>Reservoir for stool that is surgically created from a bowel loop</td>
</tr>
<tr>
<td>Recurrence</td>
<td>Renewed manifestation of disease symptoms, such as an acute flare-up in IBD</td>
</tr>
<tr>
<td>Stenosis</td>
<td>Narrowing of the bowel often caused by inflammation. Over time, long-lasting inflammation can result in scar-tissue formation that makes the narrowing permanent</td>
</tr>
<tr>
<td>Stricture</td>
<td>Another name for stenosis. Strictures, however, represent narrowing of the bowel that has become permanent due to scar-tissue formation</td>
</tr>
<tr>
<td>Stricuroplasty</td>
<td>Surgical procedure to release strictures in the bowel without excision (removal) of the entire segment of narrowed, stenotic bowel</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Subileus</td>
<td>Incomplete form of intestinal obstruction or ileus</td>
</tr>
<tr>
<td>Toxic megacolon</td>
<td>Complication occurring mostly in patients with ulcerative colitis and involving an acute dilation (ballooning) of the colon</td>
</tr>
<tr>
<td>Tumor-Necrosis-Factor (TNF)</td>
<td>Messenger substance in the human body that plays an important role in inflammatory processes</td>
</tr>
<tr>
<td>Ulcer</td>
<td>Hole or defect in the mucous membrane lining of an internal organ</td>
</tr>
</tbody>
</table>
Self help groups

Ulcerative colitis/Crohn’s disease

Australia
Australian Crohn’s and Colitis Association Inc. (ACCA)
National Office
Level 1, 462 Burwood Road
Hawthorn, VIC 3122
Tel.: +61 3 98151266
Fax: +61 3 98151299
E-Mail: info@acca.net.au
Internet: http://www.acca.net.au

Austria
Österreichische Morbus Crohn/
Colitis ulcerosa Vereinigung – ÖMCCV –
Obere Augartenstr. 26–28
A-1020 Wien
Tel./Fax: +43 1 3330633
E-Mail: office@oemccv.at
Internet: http://www.oemccv.at

Belgium
Crohn en Colitis ulcerosa Vereniging vzw (CCV)
Groeneweeg 151
B-3001 Heverlee
Tel.: +32 16 207312
Fax: +32 16 208732
E-Mail: secretariaat@ccv-vzw.be
Internet: http://www.ccv-vzw.be

Association Crohn-RCUH
Secrétariat administratif
17, rue de la Forêt de Soignes
B-1410 Waterloo
Tel./Fax: +32 2 3541285
E-Mail: fmaes.asscrohn@skynet.be
Internet: http://www.mici.be
Canada
Crohn’s and Colitis Foundation of Canada (CCFC)
National Office
600-60 St. Clair Avenue East
Toronto, ON, Canada, M4T 1N5
Tel.: +1 416 920-5035
Fax: +1 416 929-0364
E-Mail: ccfc@ccfc.ca
Internet: http://www.ccfc.ca

Czech Republic
Crocodile
Jírovcova 24
CZ-370 04 Èské Budìjovice
Tel./Fax: +420 38 6353649
E-Mail: ccd@volny.cz
Internet: http://www.volny.cz

Denmark
Colitis-Crohn-Foreningen (CCF)
Birkegade 11
DK-2200 Kopenhagen N
Tel.: +45 35354882
Fax: +45 35354782
E-Mail: ccf@ccf.dk
Internet: http://www.ccf.dk

European Federation of Crohn’s and Ulcerative Colitis Associations – EFCCA –
Mickey Lindholm, secretary
Gropmorsvagen 28
FIN-10520 Tenala
Finland
Tel.: +358 4 05778179
Fax: +358 19 2450860
E-Mail: micke.lindholm@pp.inet.fi
Internet: http://www.efcca.org
Finland
Crohn ja Colitis ry (CCAFIN)
Kuninkaankatu 24 A
FIN-33210 Tampere
Tel.: +358 3 2662600
Fax: +358 3 2662660
E-Mail: ccafin@crohnjacolitis.fi
Internet: http://www.crohnjacolitis.fi

France
Association François Aupetit (AFA)
La maison des MICI
78, quai de Jemmapes
F-75010 Paris
Tel.: +33 1 43070049
Fax: +33 1 49283189
E-Mail: info-accueil@afa.asso.fr
Internet: http://www.afa.asso.fr

Germany
Deutsche Morbus Crohn/Colitis ulcerosa
Vereinigung – DCCV – e.V.
Paracelsusstr. 15
D-51375 Leverkusen
Tel.: +49 214 87608-0
Fax: +49 214 87608-88
E-Mail: info@dccv.de
Internet: http://www.dccv.de
Great Britain
National Association for Colitis and Crohn’s Disease (NACC)
4 Beaumont House, Sutton Road
St. Albans, Herts AL1 5HH
Tel.: +44 1727 844296 or +44 1727 830038
Fax: +44 1727 862550
E-Mail: nacc@nacc.org.uk
Internet: http://www.nacc.org.uk

Hungary
Magyarországi Crohn-Coliteses Betegek Egyesülete (MCCBE)
Munkásotthon u. 41. VI/26
H-1043 Budapest
Tel./Fax: +36 1 627393652
E-Mail: mccbe@mccbe.hu
Internet: http://www.mccbe.hu

Ireland
Irish Society for Colitis and Crohn’s Disease (I.S.C.C.)
Carmichael Centre
North Brunswick Street
Dublin 7
Tel.: +353 1 8721416
Fax: +353 1 8735737
E-Mail: info@iscc.ie
Internet: http://www.iscc.ie
Italy
Associazione Malattie Infiammatorie Croniche dell’Intestino (A.M.I.C.I.)
Piazza dei Greci 5 R
I-16123 Genova
Tel.: +39 1 02464484
Fax: +39 1 02464484
E-Mail: postmaster@amiciitalia.org
Internet: http://www.amiciitalia.net

Luxembourg
Association Luxembourgeoise de la Maladie de Crohn (ALMC)
P. O. Box 648
L-2016 Luxembourg
Tel.: +352 47 509828
Fax: +352 47 982020
E-Mail: rene.manderscheid@airport.etat.lu
Internet: http://www.afa.asso.fr/luxembourg

The Netherlands
Crohn en Colitis Ulcerosa Vereniging Nederland (CCUVN)
Wilhelminastraat 45a
NL-3621 VG Breukelen
Tel.: +31 346 261001
Fax: +31 346 264974
E-Mail: info@crohn-colitis.nl
Internet: http://www.crohn-colitis.nl

Norway
Landesforeningen mot Fordøyelsessykdømmer (LMF)
c/o FFO, Smågruppesekretariatet
Postboks 4568, Nydalen
N-0404 Oslo
Tel.: +47 88005021
Fax: +47 88005031
E-Mail: lmfnorge@online.no
Internet: http://www.lmfnorge.no
Portugal
Associação Portuguesa da Doença Inflamatória do Intestino (APDI)
Rua Santa Catarina n° 92, 4° Esq.
P-4000-446 Porto
Tel.: +351 22 2086350
E-Mail: geral@apdi.org.pt
Internet: http://www.apdi.org.pt

Slovakia
Slovak Crohn Club (SCC)
Jurigovo nám. 1
SK-841 04 Bratislava
Tel.: +421 2 59327317
E-Mail: crohnclub@crohnclub.sk
Internet: http://www.crohnclub.sk

South Africa
South African Crohn’s & Colitis Association
P.O. Box 798
ZA-2055 Fourways
Tel.: +27 11 4657449
E-Mail: mossy@cybertrade.co.za
Internet: http://www.ccsg.org.za

Spain
Asociación de Enfermos de Crohn y Colitis ulcerosa de España (ACCU)
c/Hileras, 4 - 4ª planta Despachos 6 y 7
E-28013 Madrid
Tel.: +34 91 5475505
Tel./Fax: +34 91 5426326
E-Mail: accuesp@accuesp.com
Internet: http://www.accuesp.com
Sweden
Riksförbundet för Mag- och Tamssjuka (RMT)
P.O. Box 20054
S-10460 Stockholm
Tel.: +46 8 6424200
Fax: +46 8 6421100
E-Mail: rmt@magotarm.se
Internet: http://www.mago tarm.se

Switzerland
Schweizerische Morbus Crohn/
Colitis ulcerosa-Vereinigung (SMCCV)
Postcheck 50-394-6
CH-5000 Aarau
Tel.: +41 62 8248707
Tel./Fax: +41 41 6700487
E-Mail: welcome@smccv.ch
Internet: http://www.smccv.ch

USA
Crohn’s and Colitis Foundation
of America (CCFA)
386 Park Avenue South, 17th Floor
New York, NY 10016-8804
Tel.: +1 800 932-2423
+1 212 685-3440
Fax: +1 212 779-4098
E-Mail: info@ccfa.org
Internet: http://www.ccfa.org
Self help groups for patients with ileostomy

Austria
Österreichische ILCO
Obere Augartenstr. 26–28
A-1020 Wien
Tel./Fax: +43 1 3323863
E-Mail: stomaselbsthilfeilco@tele2.at
Internet: http://www.ilco.at

Great Britain
Ileostomy and Internal Pouch Support Group
Peverill House
1–5 Mill Road
Ballyclare, Co. Antrim BT39 9DR
Tel.: +44 28 93344043
Fax: +44 28 93324606
E-Mail: info@the-ia.org.uk
Internet: http://www.the-ia.org.uk

Germany
Deutsche ILCO e.V.
Thomas-Mann-Str. 40
D-53111 Bonn
Tel.: +49 228 338894-50
Fax: +49 228 338894-75
E-Mail: info@ilco.de
Internet: http://www.ilco.de

Switzerland
ilco-Schweiz
c/o Peter Schneeberger
Buchenweg 35
CH-3054 Schüpfen
Tel.: +41 31 8792468
Fax: +41 31 8792473
E-Mail: info@ilco.ch
Internet: http://www.ilco.ch

Note:
Despite checking the addresses with all due care and attention, we accept no liability for the content.
Further information for patients with inflammatory bowel disease:

- **Diet and Nutrition in Crohn’s Disease and Ulcerative Colitis**
  20 Questions – 20 Answers
  61 pages (S84e)
  *Completely revised edition 2008*

- **Crohn’s disease and its associated disorders**
  40 pages (S85e)

- **Corticosteroid therapy in inflammatory bowel diseases**
  28 pages (Bu80e)

- **Crohn’s Disease, Ulcerative Colitis and Pregnancy**
  57 pages (S82e)
  *Revised edition 2008*

These brochures can be ordered **free of charge** from Falk Foundation e.V. or the local Falk partner.

**FALK FOUNDATION e.V.**
Leinenweberstr. 5
79108 Freiburg
Germany

[www.falkfoundation.com](http://www.falkfoundation.com)